OMSAGENCT06666101
Effects of n3 LC PUFAs on Inflammatory, Immune and Senescence Features in Polyvascular Older Subjects (OMSAGE)
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Attenuation of production of inflammatory mediators
Timeframe: Day 0, Day 21
Secondary (5)
Enhanced production of proresolving mediators
Increased level of EPA and DHA
Attenuation of production of senescence-associated secretory phenotype
Attenuation of production of inflammatory mediators from immune cells
Improving immune parameters
Arms and interventions
PlaceboPlacebo comparator
Olive oil
Predominant EPAActive comparator
4 capsules MorEPA plus (Minami Neslé) daily; 590 mg EPA (20:5 n-3) and 130 mg DHA (22:6 n-3)/gels Total: 2360 mg EPA + 520 mg DHA daily; Total in n-3: 2880 mg daily
Predominant DHAActive comparator
4 capsules MorDHA (Minami Neslé) daily; 480 mg DHA (22:6 n-3) and 104 mg EPA (20:5 n-3)/gels Total: 1920 mg DHA + 416 mg EPA daily; Total in n-3: 2336 mg daily
EPA and DHA combinedActive comparator
2 capsules Mor DHA (total 1220 mg DHA) + 2 soft gels Mor EPA (total 1388 mg EPA): 2608 mg daily
Dietary supplements: Long chain polyunsaturated Omega-3, Placebo